Literature DB >> 31776000

Medical Eligibility for Contraception in Women at Increased Risk.

Thomas Römer1.   

Abstract

BACKGROUND: Most women of child-bearing age want a safe method of contraception. Numerous methods are available, with different modes of application. In situations involving particular risks, the selection of the right method poses a special challenge.
METHODS: Contraceptive methods for use in various situations with increased risk are presented in the light of a selective review of the literature, including the relevant current guidelines.
RESULTS: The current recommendations of the World Health Organization (WHO) can be used to determine whether any particular contraceptive method is applicable. In particular, the use of combined hormonal contraceptives may be contraindicated in the presence of certain risk factors, especially when there is an elevated risk of thromboembolism. Situations of increased risk include a genetic predisposition to thrombophilia, diabetes mellitus, age over 35, and nicotine abuse. Careful attention to the choice of an appropriate contraceptive agent is also necessary for women with hypertension, hepatic tumors, headache (including migraine), and epilepsy. For such patients, good alternatives include the use of a gestagen (=progesterone) single-agent preparation, an intrauterine device, or a pessary.
CONCLUSION: Meticulous history-taking and clinical examination are important components of contraceptive counseling that enable the identification of all potential risk factors. In situations of increased risk, decisions must be taken individually. Depending on the nature of the patient's underlying illness, interdisciplinary collaboration may be advisable. Even in situations of increased risk, an appropriated risk-benefit analysis should make it possible to find a suitable contraceptive method for any woman who needs one.

Entities:  

Mesh:

Year:  2019        PMID: 31776000      PMCID: PMC6916704          DOI: 10.3238/arztebl.2019.0764

Source DB:  PubMed          Journal:  Dtsch Arztebl Int        ISSN: 1866-0452            Impact factor:   5.594


  47 in total

1.  Co-prescription of antiepileptic drugs and contraceptives.

Authors:  Hao Wang; Jens H J Bos; Lolkje T W de Jong-van den Berg
Journal:  Contraception       Date:  2011-06-11       Impact factor: 3.375

Review 2.  Progestin-only contraception and thromboembolism: A systematic review.

Authors:  Naomi K Tepper; Maura K Whiteman; Polly A Marchbanks; Andra H James; Kathryn M Curtis
Journal:  Contraception       Date:  2016-05-03       Impact factor: 3.375

3.  Effectiveness of oral contraceptive pills in a large U.S. cohort comparing progestogen and regimen.

Authors:  Jürgen Dinger; Thai Do Minh; Nina Buttmann; Kristina Bardenheuer
Journal:  Obstet Gynecol       Date:  2011-01       Impact factor: 7.661

4.  Oral contraceptives and venous thromboembolism: a five-year national case-control study.

Authors:  Øjvind Lidegaard; Birgitte Edström; Svend Kreiner
Journal:  Contraception       Date:  2002-03       Impact factor: 3.375

5.  Impact of estrogen type on cardiovascular safety of combined oral contraceptives.

Authors:  Jürgen Dinger; Thai Do Minh; Klaas Heinemann
Journal:  Contraception       Date:  2016-06-22       Impact factor: 3.375

Review 6.  Hormonal contraceptive use among women with liver tumors: a systematic review.

Authors:  Nathalie Kapp; Kathryn M Curtis
Journal:  Contraception       Date:  2009-06-10       Impact factor: 3.375

Review 7.  Combined hormonal contraceptive use among obese women and risk for cardiovascular events: A systematic review.

Authors:  Leah G Horton; Katharine B Simmons; Kathryn M Curtis
Journal:  Contraception       Date:  2016-06-01       Impact factor: 3.375

8.  A survey of recommendations by gynecologists in Canada regarding oral contraceptive use in the perioperative period.

Authors:  Jennifer Oakes; Philip M Hahn; David Lillicrap; Robert L Reid
Journal:  Am J Obstet Gynecol       Date:  2002-12       Impact factor: 8.661

9.  Contemporary Hormonal Contraception and the Risk of Breast Cancer.

Authors:  Lina S Mørch; Charlotte W Skovlund; Philip C Hannaford; Lisa Iversen; Shona Fielding; Øjvind Lidegaard
Journal:  N Engl J Med       Date:  2017-12-07       Impact factor: 91.245

10.  Oral Contraceptives Use and Liver Cancer Risk: A Dose-Response Meta-Analysis of Observational Studies.

Authors:  Ning An
Journal:  Medicine (Baltimore)       Date:  2015-10       Impact factor: 1.817

View more
  3 in total

1.  Natural Family Planning.

Authors:  Claudia Wiesner
Journal:  Dtsch Arztebl Int       Date:  2020-04-03       Impact factor: 5.594

2.  In Reply.

Authors:  Thomas Römer
Journal:  Dtsch Arztebl Int       Date:  2020-04-03       Impact factor: 5.594

3.  Contraception After Bariatric Surgery.

Authors:  Athanasios Alexopoulos
Journal:  Dtsch Arztebl Int       Date:  2020-04-03       Impact factor: 5.594

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.